Stromal secreted protein acidic and rich in cysteine expression: A potential target for improved prognosis in patients with pancreatic cancer

Table 1 General characteristics of the patients, n (%)/mean ± SD

Variables, n = 91		Frequency
Age (years)		63.7 ± 9.3
Gender	Male/female	51 (56)/40 (44)
Tumor location	Head/body + tail	57 (62.3)/34 (37.4)
Radiologic tumor size (cm)		2.75 ± 1.30
Preoperative CA19-9		509.0 ± 1565.7
Operation	PPPD/DPS/TP	58 (63.7)/31 (34.1)/2 (2.2)
Tumor differentiation	Well/moderate/poor	14 (15.4)/66 (72.5)/11 (12.1)
LVI	Yes/no	29 (31.9)/62 (68.1)
PNI	Yes/no	67 (73.6)/24 (26.4)
pT stage1	T1/T2/T3	29 (31.9)/55 (60.4)/7 (7.7)
pN stage	N0/N1/N2	39 (42.9)/40 (44.0)/12 (13.2)
Retrieved LN number		19.4 ± 10.0
Metastatic LN number		1.4 ± 2.0
Adjuvant therapy	Yes/no	73 (80.2)/18 (19.8)

¹Tumor stage was assessed according to the tumor-node-metastasis classification, the American Joint Committee on Cancer 8^th edition.

CA19-9: Carbohydrate antigen 19-9; LVI: Lymphovascular invasion; PNI: Perineural invasion; LN: Lymph node; PPPD: Pancreaticoduodenectomy, preserving the pancreatic head; DPS: Disease progression score; TP: Total protein.